Precision Chroma
Next-generation chromatography for biopharmaceutical R&D and downstream purification
Precision Chroma is developing 3D-print enabled, highly ordered agarose chromatography adsorbents, designed to capture therapeutic proteins directly from unclarified bioreactor harvest. By allowing cells and debris to pass through while retaining familiar affinity chemistry and operating conditions, the technology could reduce or eliminate clarification steps while operating within existing chromatography skids and bioprocessing infrastructure.
Founded by Sean Feast, Precision Chroma is commercializing technology built on more than a decade of University of Canterbury research led by Professor Conan Fee. Sean advanced the technology through his postgraduate research before spinning out the Christchurch-based company, backed by Bridgewest Ventures. M Ventures led the seed round with participation from Bridgewest, Icehouse Ventures and Aspire NZ Seed Fund to support the company’s next phase towards GMP.